An evidence of asp viper (Vipera aspis) consumption by a western European hedgehog (Erinaceus europaeus) on Elba Island (Italy)

We report a record of consumption of an asp viper by a western European hedgehog. The observation took place in Elba Island, providing the first evidence for Italy and, to our knowledge, only the second ever in support to previous anecdotal accounts.

Comparison of Preclinical Properties of Several Available Antivenoms in the Search for Effective Treatment of Vipera ammodytes and Vipera berus Envenoming

Snakebites are a relatively rare medical emergency in Europe. In more than half of the annual cases caused by Vipera ammodytes, Vipera berus, and Vipera aspis, immunotherapy with animal-derived antivenom is indicated. Among eight products recently identified as available against European medically relevant species, only Zagreb antivenom, Viperfav, and ViperaTAb have been used almost exclusively for decades. Zagreb antivenom comprises V. ammodytes-specific F(ab′)2 fragments. Viperfav is a polyspecific preparation based on F(ab′)2 fragments against V. aspis, V. berus, and V. ammodytes venoms. ViperaTAb contains Fab fragments against the venom of V. berus. In 2014 the production of Zagreb antivenom was discontinued. Additionally, in the period of 2017 to 2018 a shortage of Viperfav occurred. Due to a lack of the product indicated for the treatment of V. ammodytes bites, other antivenoms were implemented into clinical practice without comparative assessment of their eligibility. The aim of our work was to identify a high-quality antivenom that might ensure the successful treatment of V. ammodytes and V. berus bites at the preclinical level. Differentiation between bites from these two species is difficult and unreliable in clinical practice, so the availability of a unique antivenom applicable in the treatment of envenoming caused by both species would be the most advantageous for Southeastern Europe. Zagreb antivenom, Viperfav, and ViperaTAb, as well as Viper venom antitoxin for V. berus envenoming and the in-development Inoserp Europe, which was designed to treat envenoming caused by all medically important European snakes, were comparatively tested for the first time. Emphasis was placed on their physicochemical properties, primarily purity and aggregate content, as well as their in vivo protective efficacies. As Zagreb antivenom is no longer available on the European market, Viperfav is the highest-quality product currently available and the only antivenom whose neutralisation potency against V. ammodytes and V. berus venoms was above regulatory requirements.

Only males care about their environment: sex-biased dispersal in the asp viper (Vipera aspis)

Sex-biased dispersal is common among vertebrates and numerous studies have documented a tendency towards male-biased dispersal in mammals and female-biased dispersal in birds. A few studies have demonstrated that male-biased dispersal seems to be prevalent in reptiles. However, most of these studies considered only a single study site without taking into account possible local variability. We investigated sex-biased dispersal in Vipera aspis in four study sites in Switzerland using microsatellite markers and we predicted a higher dispersal in males than females. In two study sites, females were more spatially autocorrelated and showed a stronger isolation by distance compared with males, which suggests male-biased dispersal. In the other two study sites, the absence of sex-biased dispersal could have been the result of habitat fragmentation. Surprisingly, the dispersal ability of females was similar in the four sites, regardless of habitat fragmentation. This finding suggests a limited impact of habitat on female dispersal and the opposite for male dispersal. Our study demonstrates the importance of inferring sex-biased dispersal in different habitats, because local barriers can affect the outcome of such studies. Hence, general conclusions about patterns of sex-biased dispersal should be drawn with caution when studies are conducted at a single study site.

Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae

The European continent is inhabited by medically important venomous Viperinae snakes. Vipera ammodytes, Vipera berus, and Vipera aspis cause the greatest public health problems in Europe, but there are other equally significant snakes in specific regions of the continent. Immunotherapy is indicated for patients with systemic envenoming, of which there are approximately 4000 annual cases in Europe, and was suggested as an indication for young children and pregnant women, even if they do not have systemic symptoms. In the present study, the safety and venom-neutralizing efficacy of Inoserp Europe—a new F(ab’)2 polyvalent antivenom, designed to treat envenoming by snakes in the Eurasian region—were evaluated. In accordance with World Health Organization recommendations, several quality control parameters were applied to evaluate the safety of this antivenom. The venom-neutralizing efficacy of the antivenom was evaluated in mice and the results showed it had appropriate neutralizing potency against the venoms of several species of Vipera, Montivipera, and Macrovipera. Paraspecificity of the antivenom was demonstrated as well, since it neutralized venoms of species not included in the immunization schemes and contains satisfactory levels of total proteins and F(ab’)2 fragment concentration. Therefore, this new polyvalent antivenom could be effective in the treatment of snake envenoming in Europe, including Western Russia and Turkey.

CME: Giftschlangenbisse in der Schweiz

Zusammenfassung. Obwohl Schlangenbisse in Europa insgesamt selten sind, kommt es auch in der Schweiz regelmässig zu Bissen von Giftschlangen. Zwei Giftschlangen sind in der Schweiz heimisch: die Aspisviper (Vipera aspis) und die Kreuzotter (Vipera berus). Ursächlich für die Giftschlangenbisse sind neben den heimischen Arten v.a. Bisse von exotischen Tieren, die in Terrarien gehalten werden. Ein Biss kann zu lokalen wie auch systemischen Vergiftungserscheinungen führen. Potenziell tödliche systemische Komplikationen betreffen die Hämostase, das kardiovaskuläre System wie auch das Nervensystem. Nebst einer symptomatischen Therapie besteht in der Gabe eines Antivenins die einzige kausale Therapiemöglichkeit.